Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Acer Restructures, Eliminates 29 Employees

Two weeks after the U.S. FDA rejected Acer Therapeutics’ New Drug Application for Edsivo (celiprolol), the company initiated a restructuring plan that includes the elimination of 29 employees.

Read More »

Immunomedics’ CEO and President Steps Down

Morris Plains, N.J.-based Immunomedics announced that the company’s president, chief executive officer and board member, Michael Pehl, was stepping down for personal reasons.

Read More »

FDA finds deficiencies in Mylan’s generic Advair

Mylan NV said U.S. health regulators were unable to approve the company’s generic version of GlaxoSmithKline’s blockbuster inhaled lung drug Advair for the second time, as they found “minor deficiencies” in the treatment.

Read More »

Intarcia Pink Slips 60 Employees, Ends Studies

Boston-based Intarcia Therapeutics undertook a restructuring that includes the termination of up to 60 employees and the closing of two programs.

Read More »

Ironshore Laid Off Staff, Quietly Closed Down

Almost one year after filing a New Drug Application for an ADHD drug and less than one year after announcing it secured $200 million in financing, Ironshore Pharmaceuticals closed its doors.

Read More »

TherapeuticsMD Soars on Plans to Resubmit TX-004HR NDA Without New Pre-Approval Study

Shares of TherapeuticsMD Inc. shot up more than 51 percent in morning trading after the U.S. Food and Drug Administration reversed course on its rejection of that company’s vaginal pain medication.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom